इंटेलिया: एफडीए ने एमएजीएनिट्यूड फेज 3 एटीटीआर-सीएम परीक्षण पर क्लिनिकल होल्ड हटाया

स्रोत का अंश

EX-99.1 3 d101756dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENT SM March 2, 2026 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 2 to the Open Market Sale Agreement SM , dated as of March 2, 2026, is entered into by and between Intellia Therapeutics, Inc. (the “ Company ”) and Jefferies LLC (the “ Agent ”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Sales Agreement (as defined below). WHEREAS, the Company and the Agent have entered into that certain Open Market Sale Agreement SM , dated March 4, 2022, as amended by that certain Amendment to the Open Market Sale Agreement SM , dated as of February 23, 2024 (the “ Sales A

SEC 8-K

इस संपत्ति पर और

निर्णायक

27 जन॰ 2026

01:19 pm

NTLAIntellia

इंटेलिया: एफडीए ने एमएजीएनआईटी्यूड-2 फेज 3 एटीटीआरवी-पीएन ट्रायल पर क्लिनिकल होल्ड हटाया

ट्रायल रजिस्ट्री में बदलावSEC 8-Kरिकॉर्ड खोलें

निर्णायक

6 नव॰ 2025

09:06 pm

NTLAIntellia

Intellia: FDA ने nex-z के MAGNITUDE/MAGNITUDE-2 चरण 3 परीक्षणों पर क्लिनिकल होल्ड लगाया

ट्रायल रजिस्ट्री में बदलावSEC 8-Kरिकॉर्ड खोलें

निर्णायक

25 सित॰ 2025

08:19 pm

NTLAIntellia

इंटेलिया: फेज 1 नेक्स-ज़ 3 वर्षों तक 90% टीटीआर कमी दर्शाता है

टॉपलाइन परिणामSEC 8-Kरिकॉर्ड खोलें